In general, CTLA-4 combination therapy shows enhanced antitumor efficacy, but the monotherapy of CTLA-4 inhibitors for advanced GC is still limited, and the resistance mechanism of anti-CTLA-4 treatment needs to be further studied (Jin et al., 2022). The gene discussed is CTLA4; the disease is gastric cancer.